144 related articles for article (PubMed ID: 17419693)
1. Sclerodermatous graft-versus-host disease: clinical spectrum and therapeutic challenges.
White JM; Creamer D; du Vivier AW; Pagliuca A; Ho AY; Devereux S; Salisbury JR; Mufti GJ
Br J Dermatol; 2007 May; 156(5):1032-8. PubMed ID: 17419693
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft-versus-host disease.
Calzavara Pinton P; Porta F; Izzi T; Venturini M; Capezzera R; Zane C; Notarangelo LD
Haematologica; 2003 Oct; 88(10):1169-75. PubMed ID: 14555314
[TBL] [Abstract][Full Text] [Related]
4. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy.
Creamer D; Martyn-Simmons CL; Osborne G; Kenyon M; Salisbury JR; Devereux S; Pagliuca A; Ho AY; Mufti GJ; du Vivier AW
Arch Dermatol; 2007 Sep; 143(9):1157-62. PubMed ID: 17875877
[TBL] [Abstract][Full Text] [Related]
5. Koebnerizing sclerodermatous graft-versus-host disease caused by donor lymphocyte infusion and interferon-alpha.
White JM; Devereux S; Pagliuca A; Salisbury JR; du Vivier AW; Creamer D
Br J Dermatol; 2006 Sep; 155(3):621-3. PubMed ID: 16911292
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of chronic graft-versus-host disease with extracorporeal photopheresis.
Owsianowski M; Gollnick H; Siegert W; Schwerdtfeger R; Orfanos CE
Bone Marrow Transplant; 1994 Nov; 14(5):845-8. PubMed ID: 7889018
[TBL] [Abstract][Full Text] [Related]
7. Two cases of cutaneous chronic graft versus host disease in treatment with psoralen plus ultraviolet-A-bath photochemotherapy.
Hoffner MV; Carrizosa Esquivel A; Pulpillo Ruiz A; Herrera Saval A; Conejo-Mir J; Camacho FM
J Drugs Dermatol; 2009 Nov; 8(11):1027-9. PubMed ID: 19894371
[TBL] [Abstract][Full Text] [Related]
8. Sclerodermatous chronic graft-versus-host disease--a report of four pediatric cases.
Tolland JP; Devereux C; Jones FC; Bingham EA
Pediatr Dermatol; 2008; 25(2):240-4. PubMed ID: 18429789
[TBL] [Abstract][Full Text] [Related]
9. Graft-versus-host disease after allogeneic stem cell transplantation: evolving concepts and novel therapies including photopheresis.
Komanduri KV; Couriel D; Champlin RE
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):1-6. PubMed ID: 16399595
[TBL] [Abstract][Full Text] [Related]
10. Extracorporeal photopheresis in graft-versus-host disease.
Carcagnì MR; De Aloe G; D'Ascenzo G; Rubegni P; Fimiani M
J Dtsch Dermatol Ges; 2008 Jun; 6(6):451-7. PubMed ID: 18177413
[TBL] [Abstract][Full Text] [Related]
11. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy by allogeneic stem cell transplantation.
Ringdén O
Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
[TBL] [Abstract][Full Text] [Related]
13. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA).
Vogelsang GB; Wolff D; Altomonte V; Farmer E; Morison WL; Corio R; Horn T
Bone Marrow Transplant; 1996 Jun; 17(6):1061-7. PubMed ID: 8807115
[TBL] [Abstract][Full Text] [Related]
14. PUVA-bath photochemotherapy and isotretinoin in sclerodermatous graft-versus-host disease.
Ghoreschi K; Thomas P; Penovici M; Ullmann J; Sander CA; Ledderose G; Plewig G; Kolb HJ; Röcken M
Eur J Dermatol; 2008; 18(6):667-70. PubMed ID: 18955201
[TBL] [Abstract][Full Text] [Related]
15. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?
Har-Noy M; Slavin S
Med Hypotheses; 2008; 70(6):1186-92. PubMed ID: 18054441
[TBL] [Abstract][Full Text] [Related]
16. A case of sclerodermatous graft-versus-host disease following autologous peripheral blood stem cell transplantation.
Nakamura K; Kawakami Y; Oyama N; Kaneko F; Abe H; Sagara H; Ohto H
J Dermatol; 2006 Feb; 33(2):135-8. PubMed ID: 16556284
[TBL] [Abstract][Full Text] [Related]
17. UV treatment of chronic skin graft-versus-host disease--focus on UVA1 and extracorporeal photopheresis.
Greinix HT; Tanew A
Curr Probl Dermatol; 2012; 43():116-31. PubMed ID: 22377925
[TBL] [Abstract][Full Text] [Related]
18. Induction of late graft-versus-host disease in a patient post-allogeneic stem cell transplantation by progesterone in conjunction with donor lymphocyte infusion.
Gesundheit B; Shapira MY; Maly A; Samuel S; Budowski E; Or R
Leuk Res; 2008 Mar; 32(3):501-3. PubMed ID: 17727947
[TBL] [Abstract][Full Text] [Related]
19. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of rituximab in chronic graft-versus-host disease.
Bates JS; Engemann AM; Hammond JM
Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
